Reports Archive

Targetedrelease for treating primary immunoglobulin A nephropathy as of December 2023 – Market Access Risk Assessment

MARA Rating Company December 16, 2025

These findings highlight key considerations not only for clinical outcomes but for payer response, pricing expectations, and reimbursement pathways — all of which shape market access risk in pharma and

Archives: Reports

Vyndaqel / tafamidis for treating transthyretin amyloidosis with cardiomyopathy as of June 2024

Minjuvi / tafasitamab for treating relapsed or refractory diffuse large B-cell lymphoma as of May 2023

Talzenna / talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations as of February 2024

Targetedrelease for treating primary immunoglobulin A nephropathy as of December 2023 – Market Access Risk Assessment

Kimmtrak / tebentafusp for treating advanced uveal melanoma as of January 2025

Teclistamab (tecvayli) for treating relapsed and refractory multiple myeloma after 3 or more treatments as of November 2024

Selinexor for treating multiple myeloma in adults as of May 2024

Selpercatinib / retsevmo for untreated RET fusion-positive advanced non-small-cell lung cancer as of July 2023

Selpercatinib for advanced thyroid cancer with RET alterations after treatment with a targeted cancer drug in people 12 years and over as of February 2025

Retsevmo / selpercatinib for advanced thyroid cancer with RET alterations untreated with a targeted cancer drug in people 12 years and over as of February 2025